Diclofenac topical - Novartis

Drug Profile

Diclofenac topical - Novartis

Alternative Names: Diclofenac sodium gel 1% - Novartis; Voltaren Gel

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Endo Pharmaceuticals; Novartis
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal pain
  • No development reported Acute pain

Most Recent Events

  • 20 Sep 2017 No recent reports on development identified - Phase-III for Acute pain (in patients with acute blunt soft tissue injuries/contusions) in Germany and USA (Topical)
  • 24 Mar 2016 First generic equivalent is available in USA
  • 14 Dec 2015 Endo extends its license with Novartis diclofenac topical in United States
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top